|
RealPennies.com: Turning Pennies into dollars: (OTC: HSXI), (NASDAQ:
HEPH), (OTCBB: BIPH), (PINKSHEETS: JCDS).
(M2 PressWIRE Via Thomson Dialog NewsEdge)
RDATE:08022008
Are you a public company looking for exposure? Contact RealPennies.com
- 1.800.940.6559
For more info: http://hsxi.realpennies.com
HealthSonix, Inc. (OTC: HSXI) (February 5, 2008) announced Tuesday that
it has launched a dedicated web site for its ZingiberRx Joint and
Muscle cream: www.zingiberRx.com ZingiberRx joint and muscle cream is
fast acting, non-staining, fast absorbing, and deep penetrating. Unlike
most over-the-counter topical ointments, ZingiberRx is not a
counter-irritant and does not create a hot or a cold sensation when
applied.
Medical research studies into the medicinal properties of various
plants in the ginger (Zingiberaceae) family have isolated the Zingiber
cassumunar and Zingiber officinale species for their anti-inflammatory,
anti-allergic and pain relieving properties.
"The launch of this web site coincides with on going retail sampling
and couponing programs being tested in major pharmacy chains." said
Dieter Doederlein, Vice President Corporate Development of HealthSonix.
"The response to this new pain relieving cream, the first of its kind
with ginger, continues to be very positive. We continue being a best
selling topical pain reliever at those locations. "
The Company is also launching a major online sales and marketing
campaign with Google and Yahoo adwords and banner ads on websites that
cater to the 50+ population segment: "This new marketing program has
been designed to increase awareness and promote direct to consumer
sales from our online store." added Doederlein.
HealthSonix, Inc. (OTC: HSXI) (FRANKFURT: H7S) is a publicly traded
research oriented medical technology company that develops and markets
medical devices and healthcare products for institutional and consumer
use. The company's patent pending medical devices deliver sound
pressure waves to the human body for relief of pain and other
musculoskeletal conditions. The focus is on arthritis, athletic
injuries and conditions where acute or chronic pain is the cardinal
symptom.
For more info: http://heph.realpennies.com
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ: HEPH)(February 7, 2008), the
world leader in the development of a new class of small molecule
compounds based on endogenous steroid hormones, announced earlier today
that it has commenced a Phase I/II clinical trial with its oral drug
candidate TRIOLEX (HE3286) in ulcerative colitis (UC) under an
Investigational New Drug application (IND) cleared by the U.S. Food and
Drug Administration (FDA) for this indication. The Phase I/II dose
ranging study will evaluate the safety, tolerance, pharmacokinetics and
activity of TRIOLEX when administered orally for 28 days to patients
with active, mild-to-moderate UC.
In previously reported data presented at the 3rd International
Conference on Autoimmunity last October, TRIOLEX showed significant (p
<0.05) benefit in the Wistar rat model of dinitrobenzene sulfonic acid
(DNBS) induced colitis, a preclinical model widely used by industry and
academia to test agents as potential treatments for UC. DNBS challenged
rats with induced colitis were treated orally for seven days with
either TRIOLEX or placebo (n=10 per group). At the end of the treatment
period, TRIOLEX-treated animals had significantly reduced disease, as
judged by reduced colon weight and reduced area of necrosis, compared
to the placebo-treated animals. TRIOLEX performed as well as or better
than Sulfazalazine, the standard of care used as a positive control in
this model.
TRIOLEX is a novel orally bio-available adrenal steroid hormone
analogue with anti-inflammatory and insulin sensitizing properties
currently in clinical trials under an open IND for the treatment of
metabolic disorders. The Company has also been cleared under a separate
IND with the FDA to begin clinical trials with TRIOLEX for the
treatment of rheumatoid arthritis (RA). A safety and pharmacokinetic
phase I/II clinical trial in stable RA patients on methotrexate, a
commonly used chemotherapy treatment, is currently planned to begin in
the second quarter of 2008. The Company believes that certain aspects
of the pathology driving UC are similar to those driving RA. Therefore,
data obtained in this UC study could potentially help support the
design of the Company's planned Phase II RA clinical study and help to
accelerate the development of TRIOLEX for potential use in patients
with RA.
Hollis-Eden believes the broad-based anti-inflammatory activity of
TRIOLEX may relate to a partial inhibition of the NF-kappaB pathway.
NF-kappaB is a transcription factor that controls genes whose products
are involved in the inflammatory signaling pathway, including TNF-alpha
and IL-6. These cytokines are thought to be involved in the
pathogenesis of certain autoimmune diseases such as UC and RA, and are
also implicated in the pathogenesis of metabolic diseases,
cardiovascular disorders, cancer and in general, diseases associated
with aging. Unlike currently prescribed corticosteroids that act
through the glucocorticoid receptor to completely block NF-kappaB
activation and cause immune suppression and bone loss, preclinical
models to date show that TRIOLEX does not interact with the
glucocorticoid receptor and only results in a partial inhibition of the
NF-kappaB pathway without immune suppression or bone loss.
The blood-drug concentration profiles observed in a previous Phase I
study with TRIOLEX were consistent with drug levels in the blood
associated with glycemic control and anti-inflammatory activity that
the Company has observed in previously reported preclinical models of
metabolic disorders and diseases of inflammation, respectively. TRIOLEX
also appears to have a longer half-life in humans than in rodents (5-8
hours versus 2 hours, respectively).
"Given the rapid progression of the disease flares and the clearly
defined clinical endpoints in UC, this study may potentially enable us
to demonstrate activity in humans with a short treatment course of
TRIOLEX in an acute inflammatory condition, and thereby accelerate its
potential commercialization," said Richard B. Hollis, Chairman and CEO,
Hollis-Eden Pharmaceuticals, Inc. "There are certain understood
similarities between UC and RA disease processes, so the results from
this UC trial should also enable us to optimize our Phase II clinical
trial in RA. This strategy could enable the Company to demonstrate the
safety and efficacy of TRIOLEX in acute and chronic inflammatory
conditions, both of which are treated today with currently prescribed
anti-inflammatory drugs." Ulcerative colitis is a chronic inflammation
of the large intestine, or colon, and is related to another condition
of inflammation of the intestines called Crohn's disease. UC and
Crohn's disease are frequently referred to together as inflammatory
bowel disease, or IBD. UC and Crohn's disease together affect
approximately 500,000 to 2 million people in the United States. Current
first-line anti-inflammatory drugs for the treatment of UC are topical
5-ASA compounds such as sulfasalazine-, olsalazine- and
mesalimine-based treatments. Additionally, UC is treated with
corticosteroids and immunomodulators.
Hollis-Eden Pharmaceuticals, Inc. is a world leader in the development
of a proprietary class of adrenal steroid hormones as novel
pharmaceuticals for human health. Through its Hormonal Signaling
Technology Platform, Hollis-Eden is developing a new series of small
molecule compounds that are metabolites or synthetic analogs of
endogenous hormones derived by the adrenal glands from the body's most
abundant circulating adrenal steroid. These steroid hormones, designed
to restore the biological activity of cellular signaling pathways
disrupted by disease and aging, have been demonstrated in humans to
possess several properties with potential therapeutic benefit -- they
regulate innate and adaptive immunity, reduce nonproductive
inflammation and stimulate cell proliferation. The Company's clinical
drug development candidates include TRIOLEX (HE3286), a next-generation
compound currently in clinical trials for the treatment of metabolic
disorders as well as ulcerative colitis and being prepared for clinical
trials in rheumatoid arthritis under another IND, and APOPTONE
(HE3235), a next-generation compound selected for cancer. In addition
to these clinical development candidates, Hollis-Eden has an active
research program that is generating additional new clinical leads that
are being further evaluated in preclinical models of a number of
different diseases. For more information on Hollis-Eden, visit the
Company's website at www.holliseden.com.
For more info: http://biph.realpennies.com
Biophan Technologies, Inc. (OTCBB: BIPH)(February 7, 2008), a developer
of next-generation biomedical technology, announced earlier today that
the Company has named Harold Gubnitsky to the board of directors.
Harold Gubnitsky is executive vice president of XL Techgroup, Inc., a
unique value creation company focused on inventing and growing new
companies in the biotech, ecotech, and medtech business sectors. Mr.
Gubnitsky is a seasoned executive who has worked with and within
several large, medium, and small corporations with a wide range of
responsibilities spanning executive management and operations.
In 2001, Mr. Gubnitsky founded Semtor Corporation, a technology
services company, serving as its CEO. Prior to Semtor, he was an
officer and senior executive of Proxicom, a technology business
consulting firm with a market capitalization in excess of $1.5 billion.
Previously, Mr. Gubnitsky served as vice president of Cambridge
Technology Partners where he led numerous vendor/partner relationships
and was responsible for selling and managing several Fortune 100
relationships. Prior to Cambridge, Mr. Gubnitsky served as part of the
management team at Accenture.
Commenting on the appointment, Biophan CEO John Lanzafame stated, "I am
very pleased to welcome Harold to our board. His experience in
nurturing and growing new companies in the healthcare space will be
invaluable as we continue to evolve and grow Biophan's core business."
Added Stan Yakatan, Biophan's chairman, "We are very fortunate to have
men of the caliber and expertise of Harold Gubnitsky and Travis E.
Baugh, whose appointment we announced yesterday, agree to serve on our
board of directors."
Biophan is dedicated to providing technologies that offer innovative
and competitive advantages to the medical device industry. The Company
is helping to commercialize the Myotech Circulatory Support System,
which has significant potential to improve the treatment of acute heart
failure. Biophan Technologies, Inc. holds a 68% interest in Myotech
with rights to acquire additional equity, and is leading Myotech's
business development efforts. Biophan is traded on the OTC market under
the symbol BIPH, and is also listed on the Frankfurt Stock Exchange
under the symbol BTN. For more information on Biophan, please visit our
website at www.biophan.com.
For more info: http://jcds.realpennies.com
JC Data Solutions, Inc. (PINKSHEETS: JCDS)(February 7, 2008) announced
earlier today that through its resellers Precision Products Inc. and MD
Point CMS, Inc. have delivered and installed FormGen to Midtown Surgery
Center Houston, Texas, Prestonwood Surgery Center in Dallas, Specialty
Surgery Center in Dallas, Texas, Slocum Surgery Center Portland,
Oregon, Scotts Bluff Surgery Center, Scotts Bluff, Nebraska.
This proprietary software is designed to take the multitude of forms
used by the medical field and allow preparation of patient documents in
a fraction of the time and provide manpower and costs savings.
Utilizing .NET technology and barcode processing, these forms are
electronically prepared with patient data allowing users to create,
distribute, and communicate documents that automate their information
needs.
"As expected this product can and does make an impact on productivity
within the medical services organizations that use it," states Cary
Allen, CEO, JCDS. "We continue to see sales increase and believe this
will continue to be a hot selling product for JCDS for some time to
come."
JC Data Solutions is an ACH service provider and a manufacturer of data
management systems and services. JCDS solutions are targeted to
Healthcare, Attorneys and the Oil and Gas industries.
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for
informational purposes and is not to be construed as an offer to sell
or the solicitation of an offer to buy. This report does not have
regard to the specific investment objectives, financial situation and
the particular needs of any specific person who may receive this
information. The information contained herein is based on sources that
we believe to be reliable but is not guaranteed by us as being accurate
and does not purport to be a complete statement or summary of the
available data. Past performance is no guarantee of future results.
Please consult a broker before purchasing or selling any securities
mentioned on RealPennies. For more movers:
http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the
date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
Sponsored by: http://www.isthemarketopen.com
CONTACT: RealPennies
Tel: +1 800 940 6559
e-mail: matt@realpennies.com
((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).
Copyright ? 2008 M2 Communications Ltd.
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
